Biggest Seed, Series A-E and Venture Investments within Oncology November 2023.
View the report at the bottom of this page.
November 2023 Snapshot:
59 Companies across EU and US were involved in some sort of cash movements (all indications, all cash types). From this $ 348,400,000.00 total true investment received in USA and EU within the Oncology sector in November 2023 across 21 different biotechs.
Some Notable True Oncology Investments
✅Gradalis - $9,900,000 (Grant): Phase II Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer
✅MBraceTherapeutics - $85,000,000 (Series B): Phase 1/1b study in patients with advanced metastatic solid tumors
✅ Nouscom - $72,295,505 (Series C): cancer immunotherapy based on viral vectors - Phase I, 3x Phase 1b, and 3x Phase II trials
✅ VALANX Biotech - $2,460,229 (Seed): recently added a similar conjugate targeting proliferative disease
✅ Plus 10+ companies in the report.
Acquisitions
👉 Boehringer Ingelheim acquires privately-held T3 Pharmaceuticals AG (“T3 Pharma”) T3 Pharma press release, 22ndNovember 2023
👉 TelixPharma, signed a conditional Term Sheet to acquire QSAM Biosciences, Inc. (QSAM) and its lead asset, CycloSam® (Samarium-153-DOTMP) TelixPharma press release, 14thNovember 2023
Full information on these acquisitions can be found in the report.
Click here for full report.
